WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Adamed Laboratorios S.L.U.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
VIEWS AND ANALYSIS, PHARMACY MARKET
MedRhythms | December 12, 2022
CB Insights today announced that, for the second year in a row, MedRhythms has been named to its annual Digital Health 150, a list that showcases the 150 most promising private digital health companies. This recognition comes a week after MedRhythms received the Most Valuable Digital Therapy award at the Reuters Events Pharma Awards ceremony and less than a month after MedRhythms was named a Fast Company Next Big Things in Tech honoree for the progress that the company has made on its products a...
Business Insights
Asymchem | September 17, 2021
Asymchem today announced a strategic partnership agreement to provide LaNova Medicines with one-stop services such as small molecule drugs, ADC project CMCs, R&D, production and IND China-US declaration. The collaboration between Asymchem and LaNova will include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives. This partnership will take full advantage of Asymchem's recently co...
Pharmacy Market
Orbit Discovery | March 08, 2022
Orbit Discovery a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry. Orbit will combine its leading peptide discovery platform and experience with WuXi AppTec’s downstream capabilities. Specifically, Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide p...
BioSpace | February 27, 2020
With the acquisition of San Diego-based PvP Biologics and a recent deal with COUR Pharmaceuticals, Takeda Pharmaceutical is looking to become a world leader in the treatment of celiac disease and other gastrointestinal disorders. Asit Parikh, the head of Takeda’s Gastroenterology Therapeutic Area Unit told BioSpace in an email that the acquisition of PvP and its celiac asset Kuma062, now known as TAK-062, as well last fall’s acquisition of the license for a first-in-class celiac trea...
Pharma Tech
Video
PHARMACY MARKET
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE